Allogene Therapeutics. has filed a patent for PD-1 chimeric cytokine receptors that enhance immune cell activation and potency when engaged with PD-1 ligands or anti-PD-1 antibodies. The patent also includes methods for making and using these receptors. GlobalData’s report on Allogene Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Allogene Therapeutics Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Allogene Therapeutics, Cytokine activate T-cell based compositions was a key innovation area identified from patents. Allogene Therapeutics's grant share as of January 2024 was 6%. Grant share is based on the ratio of number of grants to total number of patents.

Pd-1 chimeric cytokine receptor for immune cell activation

Source: United States Patent and Trademark Office (USPTO). Credit: Allogene Therapeutics Inc

A patent application (Publication Number: US20240016846A1) discloses a novel PD-1 chimeric cytokine receptor designed for potential therapeutic applications. The chimeric receptor comprises a PD-1 ectodomain, a transmembrane domain, a Janus Kinase (JAK)-binding domain, and a recruiting domain, with the recruiting domain being a STAT-recruiting domain in some embodiments. The receptor can be clustered or dimerized, with each monomer containing specific domains as mentioned above. The PD-1 ectodomain can have wild type sequences or mutations, including high affinity sequences, and can also include antigen binding domains for PD-1 ligands.

Furthermore, the patent application describes the use of this chimeric cytokine receptor in engineered immune cells, particularly T-cells, for potential cancer treatment. The engineered immune cells express both chimeric antigen receptors (CAR) and the chimeric cytokine receptor in stoichiometrically equal amounts. The method involves introducing the receptor-encoding polynucleotide into immune cells, which can be derived from various sources like T-cells, dendritic cells, or NK-cells. The engineered immune cells can be used in pharmaceutical compositions for cancer treatment, especially in cases where the tumor expresses PD-L1 and/or PD-L2. The method also includes administering anti-PD-1 antibodies like nivolumab or pembrolizumab in conjunction with the engineered immune cells for enhanced therapeutic effects against solid or liquid tumors.

To know more about GlobalData’s detailed insights on Allogene Therapeutics, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies